Log in to your Inderes Free account to see all free content on this page.
Modus Therapeutics Holding
0.36 SEK
-2.97 %
Less than 1K followers
MODTX
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-2.97 %
+2.57 %
-73.31 %
-37.20 %
-49.55 %
-27.15 %
-62.83 %
-
-82.65 %
Modus Therapeutics operates in biotechnology. The product portfolio includes the drug candidate sevuparin. The company's focus is to develop sevuparin for patients with sepsis, septic shock and other conditions with systemic inflammation. In addition to its core business, it also offers service and related ancillary services. The business and related research are conducted with the largest presence in Sweden.
Read moreMarket cap
43.66M SEK
Turnover
95.87K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
25.2.
2026
Annual report '25
All
Press releases
3rd party
ShowingAll content types
Modus Therapeutics publishes Interim report for the third quarter 2025
Modus Therapeutics receives regulatory approval for Part 2 of the Phase IIa study in CKD-with anemia
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio